Phase I, dose-escalation study of iodine-131 anti-B1 antibody [iodine-131 tositumomab] for patients with previously treated non-Hodgkin's lymphoma with more than 25% bone marrow involvement
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2009
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- 10 Oct 2009 Actual patient number (11) added as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.